Magnetar Financial’s Cardlytics CDLX Stock Holding History

Magnetar Financial’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-500	Closed	-$353K	–	742
2020 Q3	$353K	Buy	+500	New	+$364K	0.01%	501

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Magnetar Financial's CDLX Position: Q4 2020 in Review

Magnetar Financial sold out of Cardlytics (CDLX) in Q4 2020, closing a stake of 500 shares — an estimated $353K sold.

Magnetar Financial first reported a position in CDLX in Q3 2020 and held it in 1 quarter. The position peaked at $353K in Q3 2020. 195 funds tracked by Wall St. Rank hold CDLX as of Q4 2020.

Magnetar Financial reported no remaining Cardlytics position as of Q4 2020 after selling out during the quarter.
Magnetar Financial sold 500 Cardlytics shares in Q4 2020, an estimated $353K.
Magnetar Financial first reported a position in Cardlytics in Q3 2020 and held it in 1 quarter.
Magnetar Financial's Cardlytics position peaked at $353K in Q3 2020.
195 funds tracked by Wall St. Rank held Cardlytics as of Q4 2020.

Based on Magnetar Financial's 13F filing for Q4 2020, filed 12 Feb 2021.